text/Yangcheng Evening News All-Media Reporter Chen Hui/Respondent provided
The incidence of malignant B-cell lymphoma in my country is increasing at a rate of 3% per year. Among more than 100 types, extranodal NK/T-cell lymphoma is prone to recurrence and is difficult to treat. Once the patient is diagnosed, the prognosis is poor, and it has become a bottleneck that needs to be solved in the field of malignant lymphoma treatment. The reporter learned on September 28 that a multi-center study led by the Lymphoma Center of Sun Yat-sen University Cancer Hospital showed that after the use of the domestically produced new PDL-1 monoclonal antibody approved in my country last year, the patient's complete tumor remission rate (CR) was as high as 37.2%. The study will provide a new option for the treatment of NKT lymphoma worldwide with more accurate efficacy and fewer side effects.
uses traditional protocols to treat patients with limited benefits
Professor Huang Huiqiang , Lymphoma Center of Sun Yat-sen University Cancer Hospital, who is responsible for the study, introduced that extranodal NK/T cell lymphoma belongs to a subtype of mature T-cell and NK cell lymphoma. In 2012, a multi-center pathological analysis of 10,002 patients in my country, the disease accounts for about 6% of all different subtypes of lymphoma . Patients with disease progression after receiving standard protocols based on asparaginase lack effective rescue treatment methods and poor prognosis. Clinicians are often helpless in this type of patients because of their high malignancy and strong invasiveness, dangerous disease, rapid progress, and extremely short survival. The patient's 1-year survival rate is usually less than 20%.
Among the approved targeted drugs in China, the complete response rate of monotherapy is very low, about 6%. Patients who fail first-line treatment plans have significant unmet treatment needs.
The complete response rate of the new treatment plan is as high as 37.2%
More than two years ago, a national multi-center study led by Professor Huang Huiqiang was to evaluate the efficacy and safety of domestic new PDL-1 sugremonial mammobium in the treatment of relapsed refractory NK/T cell lymphoma. To date, this study is the first registered clinical study in the evaluation of PD-L1 monoclonal antibody treatment of R/R ENKTL.
The results of this study show that compared with past drugs, PDL-1 sugarimab significantly improved the objective response rate; among the 78 evaluable patients, the objective response rate evaluated by the independent imaging evaluation committee was 46.2%, of which the complete response rate reached 37.2%, which was 6 times higher than the previous reported treatment results.
"Our study also found that the duration of effective treatment of this drug is also quite long. The effective efficiency of 6 months and 12 months was 90.8% and 86.0% respectively. The longest patient's complete remission time has exceeded 3 years." Huang Huiqiang said that the safety of the drug is also quite high, with few adverse reactions, and can be controlled and recovered. Moreover, the incidence of clinical immunoassociation is low. Some patients have used 65 courses for a total of 3 and a half years, and no common immunotoxicity of immunomab was observed.
Professor Huang Huiqiang said that NK/T cell lymphoma is not common in terms of overall incidence, but is more common in Southeast Asia (including China), and is relatively rare in Western countries. In addition, compared with southern China, it is also relatively rare in northern China.
NK/T cell lymphoma is a highly heterogeneous disease. Most patients are primary in the nasal cavity early, while some patients are primary in the intestine, testicles or skin early. The main treatment methods for early patients are radiotherapy, while the main treatment methods for late patients are systemic chemotherapy.
In addition, the recurrence rate of NK/T cell lymphoma is still relatively high. After radiotherapy and chemotherapy in early patients, 10%-20% of patients will eventually recur; at least half of patients will recur after chemotherapy alone in advanced patients; even after using other new chemotherapy drugs or combined with autologous hematopoietic stem cell transplantation in , a considerable number of patients will recur, so this is the biggest challenge in the treatment of NK/T cell lymphoma.
"Overall, our accumulation of experience in the treatment of NK/T cell lymphoma is not as good as diffuse large B-cell lymphoma or follicular lymphoma. The accumulation of treatment experience is relatively slow due to the few cases. Therefore, the current traditional treatment methods are still difficult to completely replace.Immune-targeted therapy can improve the efficacy of standard treatment and reduce toxicity, which is a key direction of effort in the visible future. ”(For more news, please follow Yangchengpai pai.ycwb.com)
source | Yangcheng Evening News·Yangchengpai
editor | Xue Renzheng
proofreading | Zhao Dandan
